Small New Jersey firm pushes further into sterile injectables


New Jersey-based Teligent, a small specialty generic pharmaceutical company, will expand its manufacturing facility, giving it the capacity to quadruple its production.

The company will spend about $50 million to add 110,000 of space to its facility in the Atlantic City area. Peter Gallagher, Teligent’s vice president of strategic affairs, told the the press of Atlantic City, that the company expects the project to be complete next year, allowing it to double employment to about 200 people by 2018.  

Teligent will expand packaging and production, including adding a  sterile injectable manufacturing suite. The company last fall bought Canada-based Alveda Pharmaceuticals for $35.4 million, moving into the sterile injectables market in Canada.  

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Teligent reported 2015 revenues of $44.3 million.

- read the press of Atlantic City story

Related Articles: 
Pfizer building modular biologics plant in China
UPDATED: Pfizer closing Hospira plant in Colorado, 100 jobs to be lost

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.